All quotes about Amgen
Multiple people spoke about Amgen in the news. We gather all their quotes on this page, an easy way to see all views about this topic at a glance. To go deeper, all quotes are redirected to the article from which they come. Sean E. Harper is the person who had the greatest number of quotes. The most recent one of them is: “To see a more than 20 percent risk reduction for stroke was really exciting.”.
All quotes about Amgen
In fact, they may even be below the value-based range for the types of patients getting access now. We want to engage payers in risk-sharing contracts. If the drug does not perform, net prices will go down. But if the drug performs as we expect, the[...]
I think responsibly, if the number you are treating goes up and you are trying to recoup the cost of (developing) the drug ... one would hope that the price would go down.
At a cost of $7K/year, this translates to $958K per event saved. Thus, in our view, payers will continue to restrict access to the drug.
As a society we need to move to modifying these risk factors earlier in life to not only prevent recurrent events but to prevent first events.
That's the biggest issue – whether they're worth all the money.
That's a big benefit.
Endeavor is the only (relapsed multiple myeloma) study to demonstrate a survival benefit in a head-to-head comparison with a current standard of care regimen.
In light of Trump's proposal on cash repatriation, we believe AMGN could repatriate a significant portion of its $34.8B cash held overseas. The potential share buyback, dividend payment and acquisitions associated with the cash repatriation can furt[...]
[The legal fight] won't really reach a conclusion until 2018. That's the frustration sometimes of the legal situation, but the way I look at that, we're carving the landscape out as we go.
To say that you cannot wait, is that putting patients first? It's no small wonder that our industry isn't beloved.
If this industry is to survive, we have got to do the right thing by patients … and still adequately reward our investors.
To say that you cannot wait, is that putting patients first? It's no small wonder that our industry isn't beloved. If this industry is to survive, we have got to do the right thing by patients ... and still adequately reward our investors.
I think Amgen can go much higher, perhaps on comments coming out of this healthcare conference.
If Praluent was gone from the market the long-term peak sales for Repatha could move from $2 billion to $3 billion to $4 billion worldwide, in theory.
We will immediately appeal today's ruling, along with the jury's earlier finding upholding the validity of Amgen's patents. It is our longstanding position that Amgen's patent claims are invalid and that the best interests of patients will be greatl[...]
It is our longstanding position that Amgen's asserted patent claims are invalid, and we intend to appeal today's ruling.
The court's ruling today is an important step in this case and confirms the jury's finding that the patents which protect Repatha are valid and infringed by Sanofi.
We've got 13 million candidate patients ... and at least initially there will be four drugs addressing what is five times as many patients (as the RA market). We would argue that each of these drugs has the potential to be a blockbuster alongside ea[...]
Migraine today can be characterized as similar to RA in the past, in that it's a large but under-treated, and also under-diagnosed, market. The burden of disease in terms of patient quality of life, function, and resource utilization is also high. B[...]
It's crazy what's going on. They've basically destroyed our capacity to treat our patients with the drugs that we need to treat them with.
These findings suggest that the large clinical outcome trials currently underway are likely to show major benefits.
That's unbelievable. So when you get down to 24 you've got a really high chance of your plaques melting away.
We saw profound regression.
It's not like these companies are bitter enemies. These court cases are simply the last resort of original drug makers to wring a few more months or a year of exclusivity from their blockbusters.
The realization of what it's going to take to stay in this market and be successful has led to a change in the landscape and the players in it.
This was the wrong combination chosen for this evaluation, wrong duration of treatment as well, which we now know and is potentially important.
These important data further support the efficacy of AMG 334 in patients who currently have limited therapeutic options.
We are committed to bringing Erelzi to the U.S. market as soon as possible.
We believe that you're going to see consistent revenue growth, as well as improvement within operating margins over the next three to five years.
We are seeing something occur very different on the desk here. We're seeing people versus selling every rally, or shorting every rally, coming in now and buying every dip. We're seeing a big sentiment shift in general; people getting very comfortabl[...]
Migraine is the sixth leading cause of disability worldwide. Three to seven million Americans spend more than half of each month living with the debilitating symptoms of chronic migraine.
A permanent injunction is unlikely. However, the likelihood of settlement has now increased substantially with Sanofi and its partner Regeneron potentially forced to pay royalties.
Only direct clinical comparisons of (Remsima) and Remicade in active irritable bowel disease can provide the requisite assurance.
We remain on track to meet or exceed our 2018 commitments and deliver value for patients and shareholders.